Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23
Bullfrog AI Holdings (NASDAQ: BFRG) has announced an exclusive live investor webinar and Q&A session scheduled for April 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's innovative approach to drug development using AI and machine learning.
The presentation will showcase their proprietary bfLEAP™ platform, developed at Johns Hopkins Applied Physics Lab and a finalist for the R&D 100 Awards. This platform helps biopharma companies analyze high-dimensional, multi-modal data to optimize clinical strategies. The company's growth strategy focuses on two main areas: generating recurring revenue through their Data Networks platform and developing licensed drug assets in partnership with leading research institutions.
Bullfrog AI Holdings (NASDAQ: BFRG) ha annunciato un webinar esclusivo dal vivo per investitori con sessione di domande e risposte, previsto per il 23 aprile 2025 alle 16:15 ET. L'evento, organizzato da RedChip Companies, vedrà la partecipazione del CEO Vin Singh che illustrerà l'approccio innovativo dell'azienda allo sviluppo di farmaci tramite l'intelligenza artificiale e il machine learning.
La presentazione metterà in evidenza la loro piattaforma proprietaria bfLEAP™, sviluppata presso il Johns Hopkins Applied Physics Lab e finalista agli R&D 100 Awards. Questa piattaforma supporta le aziende biofarmaceutiche nell'analisi di dati ad alta dimensionalità e multi-modali per ottimizzare le strategie cliniche. La strategia di crescita dell'azienda si concentra su due aree principali: generare ricavi ricorrenti tramite la piattaforma Data Networks e sviluppare asset farmaceutici con licenza in collaborazione con istituti di ricerca di rilievo.
Bullfrog AI Holdings (NASDAQ: BFRG) ha anunciado un seminario web exclusivo en vivo para inversores con sesión de preguntas y respuestas, programado para el 23 de abril de 2025 a las 4:15 p.m. ET. El evento, organizado por RedChip Companies, contará con la participación del CEO Vin Singh, quien hablará sobre el enfoque innovador de la compañía en el desarrollo de medicamentos mediante inteligencia artificial y aprendizaje automático.
La presentación destacará su plataforma propietaria bfLEAP™, desarrollada en el Johns Hopkins Applied Physics Lab y finalista de los premios R&D 100. Esta plataforma ayuda a las empresas biofarmacéuticas a analizar datos multidimensionales y multimodales para optimizar estrategias clínicas. La estrategia de crecimiento de la empresa se centra en dos áreas principales: generar ingresos recurrentes a través de su plataforma Data Networks y desarrollar activos farmacéuticos con licencia en colaboración con instituciones de investigación líderes.
Bullfrog AI Holdings (NASDAQ: BFRG)는 2025년 4월 23일 오후 4시 15분(동부시간)에 투자자를 위한 독점 라이브 웨비나 및 질의응답 세션을 개최한다고 발표했습니다. 이 행사는 RedChip Companies가 주최하며, CEO Vin Singh가 AI와 머신러닝을 활용한 회사의 혁신적인 신약 개발 접근법에 대해 설명할 예정입니다.
프레젠테이션에서는 Johns Hopkins Applied Physics Lab에서 개발되고 R&D 100 어워드 최종 후보에 오른 독자적인 bfLEAP™ 플랫폼을 소개합니다. 이 플랫폼은 바이오제약 회사들이 고차원 다중 모달 데이터를 분석하여 임상 전략을 최적화하는 데 도움을 줍니다. 회사의 성장 전략은 두 가지 주요 분야에 집중되어 있습니다: Data Networks 플랫폼을 통한 반복 수익 창출과 선도 연구 기관과 협력하여 라이선스된 약물 자산 개발입니다.
Bullfrog AI Holdings (NASDAQ : BFRG) a annoncé un webinaire exclusif en direct pour investisseurs avec une session de questions-réponses, prévu le 23 avril 2025 à 16h15 ET. L'événement, organisé par RedChip Companies, mettra en vedette le PDG Vin Singh qui présentera l'approche innovante de la société dans le développement de médicaments grâce à l'intelligence artificielle et au machine learning.
La présentation mettra en lumière leur plateforme propriétaire bfLEAP™, développée au Johns Hopkins Applied Physics Lab et finaliste des R&D 100 Awards. Cette plateforme aide les entreprises biopharmaceutiques à analyser des données multidimensionnelles et multimodales afin d'optimiser les stratégies cliniques. La stratégie de croissance de l'entreprise se concentre sur deux axes principaux : générer des revenus récurrents via leur plateforme Data Networks et développer des actifs pharmaceutiques sous licence en partenariat avec des instituts de recherche de premier plan.
Bullfrog AI Holdings (NASDAQ: BFRG) hat ein exklusives Live-Webinar für Investoren mit einer Fragerunde angekündigt, das am 23. April 2025 um 16:15 Uhr ET stattfinden wird. Die Veranstaltung, organisiert von RedChip Companies, wird vom CEO Vin Singh geleitet, der die innovative Herangehensweise des Unternehmens an die Medikamentenentwicklung mittels KI und maschinellem Lernen vorstellt.
Die Präsentation wird ihre firmeneigene bfLEAP™ Plattform vorstellen, die im Johns Hopkins Applied Physics Lab entwickelt wurde und Finalist bei den R&D 100 Awards ist. Diese Plattform unterstützt Biopharmaunternehmen dabei, hochdimensionale, multimodale Daten zu analysieren, um klinische Strategien zu optimieren. Die Wachstumsstrategie des Unternehmens konzentriert sich auf zwei Hauptbereiche: die Generierung von wiederkehrenden Einnahmen durch ihre Data Networks Plattform und die Entwicklung lizenzierter Arzneimittel-Assets in Zusammenarbeit mit führenden Forschungseinrichtungen.
- Proprietary bfLEAP platform recognized as R&D 100 Awards finalist
- Strategic partnership with Johns Hopkins Applied Physics Lab
- Dual revenue model combining recurring platform revenue and drug asset development
- None.
GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI.
Attendees will gain insight into Bullfrog AI’s innovative use of artificial intelligence and machine learning to revolutionize drug development. The Company’s proprietary bfLEAP™ platform, developed at Johns Hopkins Applied Physics Lab and a finalist for the R&D 100 Awards, enables biopharma firms to uncover hidden biological insights and optimize clinical strategies using high-dimensional, multi-modal data. The webinar will highlight Bullfrog’s dual growth strategy—driving recurring revenue through its scalable Data Networks platform while advancing a pipeline of licensed drug assets in collaboration with top-tier research institutions.
A live question and answer session will follow the presentation.
To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_dCeoUqJ-Q_idZrNzdVAeig#/registration
Questions can be pre-submitted to BFRG@redchip.com or online during the live event.
About Bullfrog AI
Bullfrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, Bullfrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit Bullfrog AI at: https://bullfrogai.com
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com
FAQ
When is Bullfrog AI (BFRG) hosting its investor webinar and how can investors participate?
What is Bullfrog AI's (BFRG) bfLEAP platform and where was it developed?
What is Bullfrog AI's (BFRG) current business growth strategy?
How does Bullfrog AI (BFRG) use artificial intelligence in drug development?
